NEW IMPROVED METHOD OF POLYMORPHIC α FORM OF IMATINIB MESYLATE (GLEEVEC®) SYNTHESIS.
|Wojciech Łuniewski , Wojciech J. Szczepek , Łukasz S. Kaczmarek , Dorota Samson-Łazińska , Bogdan Zagrodzki , Teresa Paszkowska-Reymer|
Pharmaceutical Research Institute (IF), Rydygiera 8, Warszawa 01-793, Poland
Derivatives of N-phenyl-2-pirimidineamines 2 are valuable intermediates in manufacturing of biologically active compounds. For example, they are used in synthesis of tyrosine kinase inhibitors such as Imatinib, which is approved to treat a rare cancer called Chronic Myeloid Leukemia (CML). On XLVIII Meeting of Polish Chemical Society we revealed improved methods of compound 1 obtaining. Now we would like to show further steps, which lead to polymorphic α form of Gleevec®.
Presentation: Poster at V Multidyscyplinarna Konferencja Nauki o Leku, by Wojciech Łuniewski
See On-line Journal of V Multidyscyplinarna Konferencja Nauki o Leku
Submitted: 2006-01-26 16:18 Revised: 2009-06-07 00:44
|© 1998-2021 pielaszek research, all rights reserved||Powered by the Conference Engine|